| *Sponsored
Low Float (Nasdaq: AMIX) Has Strong Analyst Coverage And Interesting Chart Positioning
Last Month AMIX Surged Approximately 77% Intraday
July 21st Greetings, Friend!
A forward-thinking biotech company is making waves in the field with its innovative approach to managing cancer-related pain.
Recently granted clearance to expand the reach of its clinical studies, the company is now targeting several types of visceral cancers beyond its initial focus on pain associated with pancreatic cancer.
Early results from these trials have been promising, showing a significant reduction in pain, decreased dependence on opioids, and noticeable improvements in patients’ quality of life.
The technology behind this progress combines advanced nerve-mapping with highly targeted ablation methods, giving the company a distinct edge in addressing some of the most difficult aspects of pain management.
As its clinical programs gain momentum, the trajectory of this company could start drawing increased attention.
With a tight share float under 3Mn and a couple of analysts forecasting potential upside exceeding triple-digits, this Nasdaq-listed biotech looks like an attractive radar candidate.
And for those keeping track — this isn’t the first time this profile has stood out.
It was previously brought into focus late last month which was followed by a sharp rise of approximately 77% intraday, moving from $1.37 at the open to a high of $2.43 on June 27th.
Take a moment—this is one to consider keeping an eye on:
Autonomix Medical, Inc. (AMIX)
Autonomix is dedicated to transforming patient outcomes with its proprietary precision guidance technology, which is designed to sense, treat, and verify nerve activity.
By utilizing a minimally invasive procedure and novel nerve sensing technology, the company is able to identify and target specific nerves throughout the body.
Through its radio frequency (RF) ablation technology, Autonomix can then ablate responsible nerves and confirm that signaling has ceased.
This approach has the potential to revolutionize therapeutic electrophysiology and can be applied across a wide range of diseases, including chronic pain management, hypertension, and cardiology.
The Autonomix Mission
The mission of Autonomix is to dramatically improve the quality of life for millions by empowering the nerve-targeted treatments of tomorrow.
The company is committed to equipping physicians with innovative tools that enable unparalleled precision in diagnosis and treatment.
As a result, patients can expect more targeted therapies and a renewed sense of hope.
With its groundbreaking technology, Autonomix believes it can enable new procedures that were previously not possible.
Precision Approach to Pain Management
Autonomix Medical, Inc. is a medical device company focused on advancing precision nerve-targeted treatments to revolutionize the management of diseases involving the peripheral nervous system.
The company’s first-in-class platform system utilizes a catheter-based microchip sensing array antenna, which can detect and differentiate neural signals with up to 3,000 times greater sensitivity than currently available technologies.
Once target nerves are identified, Autonomix employs its proprietary radio frequency (RF) ablation technology to ablate those nerves, enabling a precision-guided sense, treat, and verify approach.
This technology addresses a broad spectrum of disease categories, from chronic pain management to hypertension and cardiology.
Autonomix is initially developing its precision nerve-targeted technology for the treatment of pain associated with pancreatic cancer.
Initial results from the company’s ongoing first-in-human study have demonstrated clinically meaningful and durable pain reduction in the first 15 responding patients.
Success in pancreatic cancer pain positions Autonomix to expand rapidly into additional cancer pain and abdominal pain indications, greatly increasing its potential market opp.
Grab Sources Here: AMIX Website. AMIX Presentation. -----
And based on multiple potential catalysts, (Nasdaq: AMIX) circles the top of my watchlist. Take a look...
#1. A Low Float Could Create Heightened Volatility Potential.
Yahoo Finance is reporting AMIX to have a float of approximately 2.4Mn shares.
What does that mean? It means that volatility potential could be significant on a daily basis.
#2. Two Analyst Targets Point To Triple-Digit Upside Potential For AMIX.
Not just one, but two different analysts are suggesting AMIX to be undervalued from current chart levels.
First off, Ladenburg Thalmann Co. Inc. analyst, Jeffrey S. Cohen, has tagged AMIX with an $18 target.
From its close on Friday, that target provides AMIX with a potential upside of over 750%!
Additionally, Maxim Group analyst, Anthony Vendettii, has given AMIX a $5.00 target.
That target gives AMIX a potential upside of 175+% from its closing valuation Friday.
#3. Autonomix Medical, Inc. Treats First Patient In Follow-On Market Expansion Phase (“PoC 2”) Of Proof-Of-Concept Human Clinical Study.
Autonomix Medical, Inc. has treated the first patient in the expanded PoC 2 phase of its proof-of-concept clinical study, targeting not only pancreatic cancer pain but also other visceral cancers.
Building on successful early results, this expansion significantly increases the technology’s reach, addressing more conditions and offering promise in a wider array of nervous system disorders and pain management applications.
#4. Autonomix Medical, Inc. Granted New U.S. Patent For Innovative Catheter-Based Platform Technology.
Autonomix Medical, Inc. has been awarded a U.S. patent for its catheter-based platform technology that enhances precision nerve-targeted treatments.
The innovation emphasizes minimally invasive approaches for conditions like chronic pain, hypertension, and neurological disorders.
Integrating advanced sensing tools and automated treatment adjustments, the technology supports broader clinical applications while expanding the company’s global intellectual property portfolio with over 80 patents.
#5. Chart Support May Be Strengthening At 4 Key Technical Levels.
AMIX ended Friday's session in a noteworthy spot on its chart.
The Nasdaq profile closed above four important technical levels, suggesting that chart support may be gaining momentum.
These four technical indicators could be building strength:
- 20-Day Simple Moving Average (SMA)
- 50-Day SMA
- 5-Day Exponential Moving Average (EMA)
- 13-Day EMA
Keep an eye on AMIX’s chart, as its 200-Day SMA might serve as significant resistance—even though that technical level remains well above $4.00. -----
It's official. Coverage is now restarted on Autonomix Medical, Inc. (Nasdaq: AMIX).
When updates are available, I'll get them out quickly. Talk soon.
All the best, Dane James Editor Market Pulse Today
(Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)
*MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 07/21/2025 and ending on 07/21/2025 to publicly disseminate information about (AMIX:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid seven thousand five hundred USD ("Funds"). To date, including under the previously described agreement, Thousand Sun Media LLC has been paid fifteen thousand USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (AMIX:US).
Please see important disclosure information here: https://marketpulsetoday.com/disclosure/amix-eueyp/#details | 
0 Response to "Low Float (Nasdaq: AMIX) Has Strong Analyst Coverage And Interesting Chart Positioning"
Post a Comment